Novacyt S.A. ("Novacyt", the "Company" or the "Group"): COVID-19 Diagnostic Tests Remain Able to Detect All Published Virus S...
21 Dezembro 2020 - 4:00AM
Business Wire
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international
specialist in clinical diagnostics, announces that following the
detection of a new variant of COVID-19 by the UK’s COVID-19
Genomics UK consortium, known as VUI-202012/01, the Company has
carried out a detailed analysis of the mutations in this new
variant and in all published COVID-19 strains to fully assess the
reliability of its existing diagnostic tests.
The results of the in silico (computer simulation) analysis of
the sequenced mutations show that the Company’s polymerase chain
reaction product portfolio, based around a single and a two gene
target for COVID-19, remain able to detect all published COVID-19
strains with the same high level of accuracy, including
VUI-202012/01.
The Company notes this new strain of the virus has also been
identified in other countries, including the Netherlands, Denmark
and Australia.
Graham Mullis, Chief Executive Officer of Novacyt,
commented:
“These data support the continued use of our tests, which remain
accurate in detecting all published strains of COVID-19, including
the latest variant. As part of our surveillance programme, we are
committed to analysing our selected gene targets for COVID-19
against new published viral sequences to demonstrate ongoing
accuracy and performance. We also remain in close contact with the
Department of Health and Social Care and the NHS as we continue to
focus our efforts on deploying our tests to hospitals and
laboratories across the UK, as well as to our customers around the
world.”
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201220005043/en/
Novacyt SA Graham Mullis, Chief Executive Officer Anthony
Dyer, Chief Financial Officer +44 (0)1276 600081 SP Angel
Corporate Finance LLP (Nominated Adviser and Broker) Matthew
Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre /
Rob Rees (Corporate Broking) +44 (0)20 3470 0470 Numis
Securities Limited (Joint Broker) Freddie Barnfield / James
Black +44 (0)20 7260 1000 Allegra Finance (French Listing
Sponsor) Rémi Durgetto / Yannick Petit +33 (1) 42 22 10 10
r.durgetto@allegrafinance.com / y.petit@allegrafinance.com FTI
Consulting (International) Victoria Foster Mitchell / Alex Shaw
/ Mary Whittow +44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
alex.shaw@fticonsulting.com / mary.whittow@fticonsulting.com FTI
Consulting (France) Arnaud de Cheffontaines +33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024